Free Trial

CRISPR Therapeutics (CRSP) Earnings Date, Estimates & Call Transcripts

CRISPR Therapeutics logo
$40.72 +0.34 (+0.84%)
(As of 12/20/2024 05:51 PM ET)

CRISPR Therapeutics Latest Earnings Summary

Actual EPS
(Nov. 5)
-$1.01 Beat By $0.41
Consensus EPS
(Nov. 5)
-$1.42

CRISPR Therapeutics posted Q3 2024 earnings on November 5, 2024, reporting an EPS of -$1.01, which beat the consensus estimate of -$1.42 by $0.41. Quarterly revenue was reported to be $0.60 million, below the consensus estimate of $6.65 million. With a trailing EPS of -$2.83, CRISPR Therapeutics' earnings are expected to decrease next year, from ($5.13) to ($5.22) per share.

Get CRISPR Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

CRSP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CRSP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

CRISPR Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20244-$1.98-$1.19-$1.59
Q2 20244-$1.98-$1.14-$1.63
Q3 20244-$1.83-$1.18-$1.55
Q4 20244-$1.52-$0.74-$1.22
FY 202416-$7.31-$4.25-$5.99
Q1 20252-$1.51-$1.03-$1.27
Q2 20252-$1.48-$0.97-$1.23
Q3 20252-$1.39-$0.92-$1.16
Q4 20252-$1.32-$0.38-$0.85
FY 20258-$5.70-$3.30-$4.50
Q1 20261-$1.40-$1.40-$1.40
Q2 20261-$1.11-$1.11-$1.11
Q3 20261-$0.60-$0.60-$0.60

CRISPR Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/5/2024Q3 2024-$1.42-$1.01+$0.41-$1.01$6.65M$0.60M
8/5/2024Q2 2024-$1.43-$1.49 -$0.06-$1.49$12.31M$0.52M
5/8/2024Q1 2024-$1.35-$1.43 -$0.08-$1.43$25.53M$0.50M
2/21/2024Q4 2023$0.15$1.10+$0.95$1.10$148.72M$201.20M
11/6/2023Q3 2023-$2.04-$1.41+$0.63-$1.41$5.05M-
8/7/2023Q2 2023-$2.13-$0.98+$1.15-$0.98$1.80M$70.00M
We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol
5/8/2023Q1 2023-$1.64-$0.67+$0.97-$0.67$24.33M$100.00M
2/21/2023Q4 2022-$2.27-$1.41+$0.86-$1.41$7.37M$6.00M

CRISPR Therapeutics Earnings - Frequently Asked Questions

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earning data on Tuesday, November 5, 2024. Learn more on CRSP's earnings history.

In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) reported ($1.01) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.42) by $0.41. Learn more on analysts' earnings estimate vs. CRSP's actual earnings.

CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $200 million.

CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of -$153.61 million. CRSP has generated -$2.83 earnings per share over the last four quarters.

CRISPR Therapeutics's earnings are expected to decrease from ($5.13) per share to ($5.22) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:CRSP) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners